Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
Date:3/11/2010

DETROIT, March 11 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE: CPD) has launched oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, which are therapeutically equivalent to Eloxatin® from Sanofi-Aventis, received approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). Oxaliplatin is an anticancer used in the treatment of colon and rectal cancer. Oxaliplatin injections have annual sales of approximately $1.3 billion in the US.

Eloxatin® is a registered trademark of Sanofi Aventis U.S. LLC

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Back to top

RELATED LINKS
http://www.caraco.com

'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
2. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  The leader in accelerated ... Drs. Sam Daher , Manal Ibrahim , ... David Couchat will be the featured microlecture presenters at ... American Association of Orthodontists (AAO) Annual Session, April 21-25, ... the microlectures beginning daily at 11:20 a.m. On the ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist ... new pediatric patients, with or without a referral. Dr. Cotey knows that interceptive ... outcome and experience. When patients receive early treatment, they may achieve straight teeth with ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce ... million gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access ... MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
Breaking Medicine News(10 mins):